Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2024年3月2日 - 6:01AM
Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative
AI drug creation company, today announced the closing of its
underwritten public offering of 19,205,000 shares of its common
stock at a public offering price of $4.50 per share, before
deducting underwriting discounts and commissions. The shares of
common stock include 2,505,000 shares pursuant to the option
granted by Absci to the underwriters, which was exercised in full.
The gross proceeds from the offering, before deducting underwriting
discounts and commissions and offering expenses, were approximately
$86.4 million. All of the shares in the offering were sold by
Absci.
Absci intends to use the net proceeds from the offering to fund
the development of its internal asset programs, continued
investment in its Integrated Drug Creation™ platform, including
related AI and wet-lab technologies, and for working capital and
other general corporate purposes.
Morgan Stanley and TD Cowen acted as joint book-running managers
for the offering.
The shares of common stock were offered by Absci pursuant to an
effective shelf registration statement on Form S-3 (File No.
333-267043) that was previously filed with the U.S. Securities and
Exchange Commission (SEC) on August 24, 2022 and became effective
on September 2, 2022. A preliminary prospectus supplement and
accompanying prospectus relating to and describing the terms of the
offering was filed with the SEC on February 27, 2024. The final
prospectus supplement and accompanying prospectus relating to the
offering was filed with the SEC on February 28, 2024 and may be
obtained from Morgan Stanley & Co LLC, Attention: Prospectus
Department, 180 Varick Street, 2nd Floor, New York, New York 10014,
by telephone: (866) 718-1649, or by email at
prospectus@morganstanley.com; Cowen and Company, LLC, 599 Lexington
Avenue, New York, NY 10022, by telephone at (833) 297-2926 or by
email at Prospectus_ECM@cowen.com; or by accessing the SEC’s
website at www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Absci
Absci is a data-first generative AI drug creation company that
combines AI with scalable wet lab technologies to create better
biologics for patients, faster. Our Integrated Drug Creation™
platform unlocks the potential to accelerate time to clinic and
increase the probability of success by simultaneously optimizing
multiple drug characteristics important to both development and
therapeutic benefit. With the data to train, the AI to create, and
the wet lab to validate, we can screen billions of cells per week,
allowing us to go from AI-designed antibodies to wet lab-validated
candidates in as little as six weeks. Absci’s headquarters is in
Vancouver, WA, with its AI Research Lab in New York City and an
Innovation Center in Zug, Switzerland.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Absci’s anticipated public offering. The words “may,”
“might,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,”
“predict,” “future,” “project,” “potential,” “continue,” “target”
and similar words or expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Any forward-looking statements in this press release, such as
the intended use of proceeds, are based on management’s current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release. These
and other risks and uncertainties are described in greater detail
in the section entitled “Risk Factors” in Absci’s Annual Report on
Form 10-K for the year ended December 31, 2022, as amended, and
Quarterly Reports on Form 10-Q for the quarters ended March 31,
2023, June 30, 2023 and September 30, 2023, as well as discussions
of potential risks, uncertainties, and other important factors in
Absci’s other filings with the SEC, including those contained or
incorporated by reference in the prospectus supplement and
accompanying prospectus related to the public offering filed with
the SEC. In addition, any forward-looking statements contained in
this press release represent Absci’s views only as of the date
hereof and should not be relied upon as representing its views as
of any subsequent date. Absci explicitly disclaims any obligation
to update any forward-looking statements, except as required by
law. No representations or warranties (expressed or implied) are
made about the accuracy of any such forward-looking statements.
Investor ContactAlex KhanVP, Finance &
Investor Relationsinvestors@absci.com
Media Contactpress@absci.com
AbSci (NASDAQ:ABSI)
過去 株価チャート
から 5 2024 まで 6 2024
AbSci (NASDAQ:ABSI)
過去 株価チャート
から 6 2023 まで 6 2024